Acta Neurologica Scandinavica

Papers
(The H4-Index of Acta Neurologica Scandinavica is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Neurological side effects of SARS‐CoV‐2 vaccinations112
The potential neurological effect of the COVID‐19 vaccines: A review82
Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta‐analysis42
Parkinson’s disease and intensive exercise therapy — An updated systematic review and meta‐analysis41
Glymphatic dysfunction in isolated REM sleep behavior disorder40
Neutrophil–lymphocyte ratio in acute ischemic stroke: Immunopathology, management, and prognosis39
COVID‐19 presentations and outcome in patients with epilepsy35
Blood biomarkers in ALS : challenges, applications and novel frontiers33
Blood biomarkers for Alzheimer's disease and related disorders33
Refractory migraine profile in CGRP‐monoclonal antibodies scenario31
Neutrophil‐to‐lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review29
Microglia and immunotherapy in Alzheimer’s disease27
Persistent olfactory dysfunction after COVID‐19 is associated with reduced perfusion in the frontal lobe26
Systolic blood pressure variability following endovascular thrombectomy and clinical outcome in acute ischemic stroke: A meta‐analysis26
SARS‐CoV‐2 vaccines are not free of neurological side effects25
Vagus nerve stimulation in patients with Lennox‐Gastaut syndrome: A meta‐analysis25
Telehealth approach for amyotrophic lateral sclerosis patients: the experience during COVID‐19 pandemic24
Blood biomarkers of peripheral neuropathy23
Effectiveness of clinical exome sequencing in adult patients with difficult‐to‐diagnose neurological disorders23
Potassium channels and epilepsy23
Multiple cranial nerve palsies following COVID‐19 vaccination—Case report23
Multiple sclerosis and COVID‐19: The Swedish experience22
0.051882982254028